Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models

[1]  E. M. Sánchez Robles,et al.  Cannabinoids and muscular pain. Effectiveness of the local administration in rat , 2012, European journal of pain.

[2]  R. Abalo,et al.  Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes , 2012, Pharmacology Biochemistry and Behavior.

[3]  K. Varani,et al.  7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists. , 2012, Journal of medicinal chemistry.

[4]  M. di Luca,et al.  Increased [3H]D‐aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse , 2012, Journal of neuroscience research.

[5]  K. Varani,et al.  Retracted: Cannabinoid CB2 receptors modulate ERK‐1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide , 2012, British journal of pharmacology.

[6]  L. Devi,et al.  The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.

[7]  G. F. Passos,et al.  Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in mice , 2011, PAIN®.

[8]  R. Schechter,et al.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms. , 2011, Pharmacology & therapeutics.

[9]  W. Kim,et al.  Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model , 2011, Neuroscience Letters.

[10]  K. Varani,et al.  A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. , 2011, American journal of respiratory and critical care medicine.

[11]  P. Chandran,et al.  Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats , 2011, British journal of pharmacology.

[12]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[13]  E. Hermans,et al.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. , 2010, Biochemical pharmacology.

[14]  K. Mackie,et al.  CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.

[15]  S. Llames,et al.  Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer‐induced pain , 2010, British journal of pharmacology.

[16]  Q. Pittman,et al.  Cannabinoid CB2 Receptors in Health and Disease , 2010 .

[17]  P. Mantyh,et al.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. , 2010, Life sciences.

[18]  G. Homanics,et al.  Prototypic GABAA Receptor Agonist Muscimol Acts Preferentially Through Forebrain High-Affinity Binding Sites , 2010, Neuropsychopharmacology.

[19]  K. Varani,et al.  Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. , 2010, Biochemical pharmacology.

[20]  A. Hohmann,et al.  Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside , 2009, Neurotherapeutics.

[21]  T. Yamaji,et al.  Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats , 2009, Neuropharmacology.

[22]  Cheol-Whan Lee,et al.  CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. , 2009, Cardiovascular research.

[23]  N. Stella,et al.  The therapeutic potential of novel cannabinoid receptors. , 2009, Pharmacology & therapeutics.

[24]  G. Geisslinger,et al.  The IKK‐NF‐κB pathway: a source for novel molecular drug targets in pain therapy? , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Bujalska.  Effect of Cannabinoid Receptor Agonists on Streptozotocin-Induced Hyperalgesia in Diabetic Neuropathy , 2008, Pharmacology.

[26]  Y. Korchev,et al.  Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons , 2008, PAIN.

[27]  A. A. Mongin,et al.  Activation of microglia with zymosan promotes excitatory amino acid release via volume‐regulated anion channels: the role of NADPH oxidases , 2008, Journal of neurochemistry.

[28]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[29]  S. Fidecka,et al.  Interaction of memantine and ketamine in morphine- and pentazocine-induced antinociception in mice. , 2008, Pharmacological reports : PR.

[30]  A. Hohmann,et al.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.

[31]  G. Cabral,et al.  CB2 receptors in the brain: role in central immune function , 2008, British journal of pharmacology.

[32]  J. Romero,et al.  Cannabinoid CB2 receptors in human brain inflammation , 2008, British journal of pharmacology.

[33]  Y. Nakata,et al.  The release of substance P from cultured dorsal root ganglion neurons requires the non-neuronal cells around these neurons. , 2007, Journal of pharmacological sciences.

[34]  M. Zarrindast,et al.  Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice , 2007, Behavioural pharmacology.

[35]  K. Valenzano,et al.  The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. , 2007, Current medicinal chemistry.

[36]  W. Willis,et al.  Intradermal injection of capsaicin induces acute substance P release from rat spinal cord dorsal horn , 2006, Neuroscience Letters.

[37]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[38]  T. Sun,et al.  Alleviation of neuropathic pain by intrathecal injection of antisense oligonucleotides to p65 subunit of NF-kappaB. , 2006, British journal of anaesthesia.

[39]  R. Bertorelli,et al.  CB2 receptor‐mediated antihyperalgesia: possible direct involvement of neural mechanisms , 2006, The European journal of neuroscience.

[40]  Ken Mackie,et al.  Cannabinoid receptors as therapeutic targets. , 2006, Annual review of pharmacology and toxicology.

[41]  A. Dyson,et al.  Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat , 2005, Pain.

[42]  Yumi Yamada,et al.  Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways. , 2004, American journal of respiratory and critical care medicine.

[43]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[44]  P. Soubrié,et al.  SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization , 2004, Journal of Pharmacology and Experimental Therapeutics.

[45]  C. Stucky,et al.  Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1 , 2003, Pain.

[46]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[47]  T. O'reilly,et al.  A rat model of bone cancer pain , 2002, Pain.

[48]  L. Urbán,et al.  The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. , 2001, Pain.

[49]  A. Gomtsyan,et al.  ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. , 2000, The Journal of pharmacology and experimental therapeutics.

[50]  K. Klotz,et al.  [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. , 2000, Molecular pharmacology.

[51]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[52]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Kimelberg,et al.  Release of [3H]-d-Aspartate from Primary Astrocyte Cultures in Response to Raised External Potassium , 1996, The Journal of Neuroscience.

[54]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[55]  R. F. Westbrook,et al.  The formalin test: scoring properties of the first and second phases of the pain response in rats , 1995, Pain.

[56]  P. Sandroni,et al.  International association for the study of pain , 1986, Pain.

[57]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[58]  M. Tognon,et al.  A3 RECEPTORS ARE OVEREXPRESSED IN PLEURA FROM PATIENTS WITH MESOTHELIOMA AND REDUCE CELL GROWTH VIA AKT/NUCLEAR FACTOR-KB PATHWAY , 2011 .

[59]  Q. Pittman,et al.  Cannabinoid CB(2) receptors in health and disease. , 2010, Current medicinal chemistry.

[60]  V. Marzo.  Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight , 2010, Nature Neuroscience.

[61]  E. Milligan,et al.  Cannabinoids for the treatment of neuropathic pain: clinical evidence. , 2008, Current opinion in investigational drugs.

[62]  G. Barbara,et al.  Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.

[63]  Y. Nakata,et al.  CB(1) cannabinoid receptor stimulation modulates transient receptor potential vanilloid receptor 1 activities in calcium influx and substance P Release in cultured rat dorsal root ganglion cells. , 2005, Journal of pharmacological sciences.

[64]  Y. Nakata,et al.  CB1 Cannabinoid Receptor Stimulation Modulates Transient Receptor Potential Vanilloid Receptor 1 Activities in Calcium Influx and Substance P Release in Cultured Rat Dorsal Root Ganglion Cells , 2005 .

[65]  P. Soubrié,et al.  carboxamide ] , a New Potent and Selective Antagonist of the CB 1 Cannabinoid Receptor : Biochemical and Pharmacological Characterization , 2004 .

[66]  K. Klotz,et al.  [3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. , 2000 .